March - 2019

MECFA Blog

Vertex Pharma (VRTX) Receives Approval for SYMDEKO in Australia to Treat Underlying Cause of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods Administration (TGA) of Australia has...

Gene Therapy

Cystic fibrosis (CF) is a rare, heritable disease caused by mutations in the CFTR gene, which provides instructions for making the CFTR...

Genetic Counseling

Cystic fibrosis (CF) is a genetic disease caused by mutations in the CFTRgene resulting in the buildup of thick, sticky mucus in various...

Lower Oxygen Levels During Exercise Is a Risk Factor for Osteoporosis in Non-CF Bronchiectasis, Stud

Decreased blood oxygen levels during the six-minute walk test (6MWT) is a risk factor for osteoporosis in patients with non-cystic...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says